Please assess the completion status of the following clinical trial:

Trial Title: A First in Human Study of STT-5058, an Antibody That Binds ApoC3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* in good health~* Able to comprehend and willing to sign an ICF and to abide by the study restrictions.~* Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception Parts A, B and D~* BMI between 18 and 35 kg/m2 inclusive~* Fasting Triglycerides between 150 and 400mg/dL inclusive Part C~* Fasting Triglycerides between 200 and 400 mg/dL inclusive~* Fasting LDL-C between 70 and 160 mg/dL inclusive~* BMI between 18 and 40 kg/m2~Exclusion Criteria:~* significant history or clinical manifestation of metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator~* Confirmed (eg, 2 consecutive measurements) systolic blood pressure \>150 or \<90 mmHg, diastolic blood pressure \>90 or \<50 mmHg, and heart rate \>90 or \<40 beats per minute at Screening, Check-in, or prior to dosing on Day 1.~* History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.~* Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days or 5 half-lives (if known), whichever is longer, prior to dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- STT-5058 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).